EMBER Imlunestrant in BC
EMBER: Phase Ia/b Study of Imlunestrant, a Next-Generation Oral SERD, in Advanced ER+/HER2- Breast Cancer

Released: October 27, 2023

Activity

Progress
1
Course Completed